PRCT250117C135000
- 0.90
- 0.000.00%
PROCEPT BioRobotics Newsroom
Express News | CITIC SEC: The year of mass production for Optimus is expected to inject strong confidence into the humanoid robot Sector.
Musk: The goal this year is to produce thousands of Siasun Robot&Automation humanoid robots, with production increasing tenfold each year over the next two years.
Musk stated that if everything goes smoothly, the production of humanoid robots will increase tenfold by 2026, with the goal of producing between 0.05 million to 0.1 million humanoid robots next year, and then increasing it tenfold again the following year.
NVIDIA open-sources the world's foundational models, humanoid robots accelerate towards the 'ChatGPT moment'.
① Recently, NVIDIA launched the physical AI model Cosmos, which is capable of predicting environments such as warehouses and road conditions to train Siasun Robot&Automation; ② According to NVIDIA's disclosed list, the first batch of users for Cosmos includes manufacturers such as 1X, Agility, Figure AI, and Xiaopeng Autos; ③ Brokerages believe that in the collection methods of training data for humanoid robots, synthetic data will greatly promote the development of robots.
Supported by NVIDIA and Tesla! The Global robotics market may experience a major explosion, and these Concept stocks are likely to take off.
Jensen Huang once exclaimed, "The era of Siasun Robot&Automation is about to arrive."
Institutional Investors in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) See US$446m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them.
BTIG Maintains PROCEPT BioRobotics(PRCT.US) With Hold Rating
Wells Fargo Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Raises Target Price to $112
Procept Biorobotics Insider Sold Shares Worth $2,584,638, According to a Recent SEC Filing
Morgan Stanley Bullish on Medtech in 2025, Upgrades 5 Stocks
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
PROCEPT BioRobotics Initiated at Overweight by Morgan Stanley
PROCEPT BioRobotics Analyst Ratings
Morgan Stanley Initiates PROCEPT BioRobotics(PRCT.US) With Buy Rating, Announces Target Price $105
PROCEPT BioRobotics: Strong Market Positioning and Growth Potential With Aquablation Technology and Hydros System
Leerink Partners Sticks to Their Buy Rating for PROCEPT BioRobotics (PRCT)
PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024
Express News | Procept Biorobotics Corp : Leerink Partners Cuts Target Price to $102 From $103
Alkermes, DaVita, Jabil, Ralph Lauren, Among Potential M&A Candidates - BofA
PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 29% Jump Shows Its Popularity With Investors